Ask AI
ASCO 2025 Breast Cancer

CE / CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: July 31, 2025

Expiration: January 30, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this text-based module, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, summarize and review the clinical implications of key studies in breast cancer presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

How likely would you be to consider T-DXd + pertuzumab as first-line therapy for patients with advanced HER2+ breast cancer should this combination be approved based on data from the phase III DESTINY-Breast09 trial?

Which of the following therapies was shown to significantly prolong median PFS in patients with advanced HR+/HER2- breast cancer developing an ESR1 mutation while receiving first-line therapy with an AI + CDK4/6 inhibitor in the phase III SERENA-6 trial?

Which of the following findings was reported from the phase III ASCENT-04 trial that compared first-line sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in patients with advanced PD-L1–positive TNBC?

Which of the following was reported at ASCO 2025 in a patient-reported outcomes analysis from the phase III EMBER-3 trial that compared imlunestrant with or without abemaciclib vs standard of care (SoC) endocrine therapy (ET) in patients with advanced estrogen receptor (ER)-positive/HER2-negative breast cancer and disease progression on or following AI ± CDK4/6 inhibitor therapy?

Which of the following was reported at ASCO 2025 in a subset analysis by menopausal status and age from the phase III NATALEE study comparing the addition of ribociclib to adjuvant ET with a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with intermediate- to high‑risk HR-positive/HER2-negative early breast cancer (EBC)?